Skip to main content

COVID 19 Updates from RheumNow

RheumNow Podcast – Pounds of Prevention (3.5.2021)

Dr. Jack Cush reviews nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Baricitinib Therapy in Covid-19 Pneumonia

The NEJM has published the results of the ACCT-2 Study,  a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery.

Paucity of Effectiveness Research on Telemedicine in RA

A systematic review of telehealth in delivering equivalent care in rheumatoid arthritis (RA) patients demonstrates there is limited evidence that virtual RA care is equivalent to conventional face-to-face (F2F) care; thus despite current widespread use there is a great need for credible well-desi

NEJM: Interleukin-6 Inhibition in Critically-Ill COVID-19

The pendulum and jury are wavering with regard to the benefits of interleukin-6 receptor antagonists in COVID-19; the current NEJM reports the results of a study favoring such biologic therapy in in critically ill COVID-19 patients.

RWCS Highlights - Day 3

Today I’ve included some research and clinical pearls as well as fodder for your post COVID-19 dinner party or trivia night!  Enjoy!

Psoriatic Arthritis: 2020 Year in Review: with Drs. Alexis Ogdie, Artie Kavanaugh, and Eric Ruderman

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease (RMD) patients, based on the efforts of the North American Task force.

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,

IVIg in MIS-C

Among children with multisystem inflammatory syndrome (MIS-C), treatment with IVIG and methylprednisolone vs IVIG alone was associated with a more favorable fever course. MIS-C is a rare but serious pediatric condition associated with COVID-19 where different body parts can become inflamed, inclu

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Hydroxychloroquine Fails to Prevent COVID-19

There is a preponderance and mounting evidence that hydroxychloroquine (HCQ) is ineffective in COVID-19 infection; and now the NEJM reports a the results of a trial where HCQ given as post-COVID exposure therapy failed to prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy pe

Adverse Events with Anti-malarials during the COVID Pandemic

For a variety of reasons, the use of anti-malarials (chloroquine and hydroxychloroquine) rose dramatically in the pandemic; notable was the lack of proven benefit and the dramatic risk in reported adverse drug reactions (ADRs) associated with these drugs being used to treat SARS-CoV-2.

Consults in Cars

In this episode of Dialing for Doctors (AKA Tales of Telehell), we will consider a growing subset of telehealth seekers connecting from their cars.

I don’t mean they are driving to the clinic, or driving to a virtual care center.  

Social

Its sill not SAFE! Avoid congregate settings! CDC report shows among 81 who participated in indoor high-intensity exercise classes - 68% developed COVID-19. 40% with COVID-19 attended class on day Sxs began. Most (76%) wore masks infrequently https://t.co/KLZauJUupN

Dr. John Cush @RheumNow ( View Tweet )

6 days 18 hours ago
In Israel (as of Feb 2021) 84% of those ≥70 years and 10% for <50 years have received 2 doses of the COVID Vaccine; as such the need for mechanical ventilation in the elderly has declined 67% with the implementation of COVID vaccines. https://t.co/9Qnv72QYUS

Dr. John Cush @RheumNow ( View Tweet )

6 days 19 hours ago
My Experience as a COVID19 Vaccine Trial Participant https://t.co/ILfXLUL8IZ

Dr. John Cush @RheumNow ( View Tweet )

1 week ago
Email Survey study of HSS rheumatic pts 7,094 responded 1,547 were women (18-50yrs) & 61 (4%) were pregnant during COVID. COVID prevalence was similar in PREG vs nonPREG (8% vs.9% ), PREG COVID pts had shorter Sxs, more loss taste/smell. https://t.co/4HDuXbZVrs

Dr. John Cush @RheumNow ( View Tweet )

2 weeks 3 days ago
Common mucocutaneous findings in 35 kids w/ MIS-C & COVID: 1) conjunctival injection (21), palmoplantar erythema (18), lip hyperemia (17), periorbital erythema/edema (7), strawberry tongue (8), & malar erythema (6) https://t.co/mcSOXtXaEh

Dr. John Cush @RheumNow ( View Tweet )

2 weeks 4 days ago
Could the PEG portion be responsible for IgE and non-IgE mediated COVID vaccine reactions? Both Moderna and Pfizer use the same 2000kd PEG for stability of the lipid nanoparticle. (Recall Miralax and PEG reactions...) Dr. A Postolova #RWCS2021 #RWCS @RWCSmtg @RheumNow https://t.co/ALXvR2h21z
Dr. Rachel Tate @uptoTate ( View Tweet )
3 weeks 2 days ago
Vaccinated COVID-19 pts appear less contagious; report from Israel - among 650,000 received two-doses of Pfizer vaccine, 2,897 later tested positive for COVID-19, but nasal swab samples showed 4-fold less virus - hinting protection https://t.co/UBE4q6aE63

Dr. John Cush @RheumNow ( View Tweet )

3 weeks 2 days ago
ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients The ACR has published a draft guidance on the use of COVID-19 vaccination in RMD patients, based on the efforts of the North American Task Force. https://t.co/uSPfvJB8EC https://t.co/9bwBdtHw5e
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 2 days ago
Preprint from UK trial shows tocilizumab efficacy in COVID-19. 2022 TCZ vs 2094 usual care pts (also on dexamethasone), in hospitalized pts on ventilators. 28 day mortality was 29% on TCZ Vs 33% with usual care - TCZ had 23% incr probability of discharge https://t.co/Curd6W20qK https://t.co/0TbhJYh5vM
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 3 days ago
Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in RMD according to a French cohort study. https://t.co/8rh1YvtqoE https://t.co/dxVGkdTPKg
Dr. John Cush @RheumNow ( View Tweet )
3 weeks 3 days ago
×